Clinical Trial Update: Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) [Phase 2]

View source ↗

Summary

Phase 2 study of burosumab (KRN23) in pediatric X-linked hypophosphatemia completed; results posted evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Burosumab (Crysvita) (burosumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: X-linked Hypophosphatemia | Phase 2 | Status: COMPLETED | Results posted: 2019-05-22